Efficient depletion of alloreactive donor T lymphocytes based on expression of two activation-induced antigens (CD25 and CD69)

被引:56
作者
Fehse, B [1 ]
Frerk, O [1 ]
Goldmann, M [1 ]
Bulduk, M [1 ]
Zander, AR [1 ]
机构
[1] Univ Hamburg, Hosp Eppendorf, D-20251 Hamburg, Germany
关键词
T-cell depletion; alloreactivity; CD25; CD69; magnetic cell sorting;
D O I
10.1046/j.1365-2141.2000.02074.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
T lymphocytes play an important role in allogeneic bone marrow/stem cell transplantation by supporting engraftment and immune recovery. Moreover, donor T cells have been shown to mediate the so-called graft-versus-leukaemia effect and are, therefore, increasingly used for adoptive immunotherapy. However, T-cell infusions are associated with the risk of a graft-versus-host reaction, which may lead to a life-threatening disease. To overcome this problem, we followed a new strategy for the exclusive depletion of alloreactive cells. We activated allogeneic T cells by cultivation on an adherent cell layer derived from peripheral blood, We then depleted activated cells based on the expression of CD25, CD69 or both activation-induced antigens using magnetic cell sorting. Mixed lymphocyte culture (MLC) reactions and helper T-lymphocyte precursor cell frequency (HTLP-f) assays demonstrated that this technique led to a significant decrease in alloreactivity of 'donor' cells, which at the same time preserved reactivity against third-party cells. The lowest level of alloreactivity was found when CD25 and CD69 antibodies were used together for depletion. This corresponds with our observation that expression of CD25 or CD69 may partially represent different activation pathways. We conclude that ex vivo depletion of CD25- and CD69-expressing alloreactive cells may help to overcome limitations of adoptive immunotherapy.
引用
收藏
页码:644 / 651
页数:8
相关论文
共 31 条
[1]  
ANTIN JH, 1991, BLOOD, V78, P2139
[2]   Establishment of an optimised gene transfer protocol for human primary T lymphocytes according to clinical requirements [J].
Ayuk, FA ;
Li, Z ;
Kühlcke, K ;
Lindemann, C ;
Schade, UM ;
Eckert, HG ;
Zander, AR ;
Fehse, B .
GENE THERAPY, 1999, 6 (10) :1788-1792
[3]   Graft-versus-leukaemia: Understanding and using the alloimmune response to treat haematological malignancies [J].
Barrett, AJ ;
Malkovska, V .
BRITISH JOURNAL OF HAEMATOLOGY, 1996, 93 (04) :754-761
[4]   HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia [J].
Bonini, C ;
Ferrari, G ;
Verzeletti, S ;
Servida, P ;
Zappone, E ;
Ruggieri, L ;
Ponzoni, M ;
Rossini, S ;
Mavilio, F ;
Traversari, C ;
Bordignon, C .
SCIENCE, 1997, 276 (5319) :1719-1724
[5]  
Caruso A, 1997, CYTOMETRY, V27, P71, DOI 10.1002/(SICI)1097-0320(19970101)27:1<71::AID-CYTO9>3.0.CO
[6]  
2-O
[7]   SPECIFIC ELIMINATION OF ALLOREACTIVE T-CELLS BY AN ANTI-INTERLEUKIN-2 RECEPTOR B-CHAIN-SPECIFIC IMMUNOTOXIN [J].
CAVAZZANACALVO, M ;
FROMONT, C ;
LEDEIST, F ;
LUSARDI, M ;
COULOMBEL, L ;
DEROCQ, JM ;
GEROTA, I ;
GRISCELLI, C ;
FISCHER, A .
TRANSPLANTATION, 1990, 50 (01) :1-7
[8]  
CHAMPLIN R, 1990, BLOOD, V76, P418
[9]   Temporal dynamics of CD69 expression on lymphoid cells [J].
Craston, R ;
Koh, M ;
Mc Dermott, A ;
Ray, N ;
Prentice, HG ;
Lowdell, MW .
JOURNAL OF IMMUNOLOGICAL METHODS, 1997, 209 (01) :37-45
[10]  
DATTA AR, 1994, BONE MARROW TRANSPL, V14, P517